New insider activity at Ionis Pharmaceuticals ( (IONS) ) has taken place on February 4, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Frank C. Bennett, Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, recently executed a sizable stock sale, disposing of 85,089 shares of the company. The transaction carried a total value of $7,055,488, underscoring a significant monetization of his equity position in the biotech firm.
Recent Updates on IONS stock
Over the last day, Ionis Pharmaceuticals has seen notable bullish sentiment as multiple positive developments emerged. Barclays assumed coverage with an optimistic stance on both Ionis and the broader biotech sector, citing a favorable 2026 setup driven by expectations of continued M&A activity, strong industry fundamentals, undervaluation across many biotech names, and easing concerns around drug pricing. Separately, Wells Fargo increased its valuation outlook for Ionis based on the company’s strong 2025 performance and the prospect of further value creation from several key 2026 catalysts, including pivotal Phase 3 readouts for bepirovirsen in chronic hepatitis B, pelacarsen in lipoprotein(a), and WAINUA in ATTR-CM. Ionis also reported that its partner GSK delivered successful Phase 3 B-Well 1 and B-Well 2 trial results for bepirovirsen, demonstrating clinically meaningful functional cure rates and an acceptable safety profile, which supports upcoming global regulatory submissions and future milestone and royalty revenue potential. In addition, the European Commission approved Dawnzera for preventing recurrent hereditary angioedema attacks in eligible patients, enhancing Ionis’s commercial portfolio and contributing to positive technical momentum in the stock, even as analysts still note ongoing profitability and cash-flow risks in the background.
Spark’s Take on IONS Stock
According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses, leverage, and negative operating/free cash flow). Offsetting this, technicals are positive and recent updates (raised revenue guidance, product momentum, and multiple Phase 3/regulatory wins) improve the growth outlook, but profitability and cash flow risk remain the key constraint.
To see Spark’s full report on IONS stock, click here.
More about Ionis Pharmaceuticals
YTD Price Performance: 6.93%
Average Trading Volume: 2,440,499
Technical Sentiment Signal: Buy
Current Market Cap: $13.46B